TeleflexLogo.jpg
Published Data Demonstrate Consistent PUL Outcomes for the Treatment of Median Lobe Obstruction Across Controlled and Real-World Settings
October 25, 2022 06:30 ET | Teleflex Incorporated
Men with obstructive median lobes treated with the UroLift® System experience symptom improvement sooner and are satisfied more quickly compared to those treated with TURP, and have fewer post-op...
TeleflexLogo.jpg
Teleflex Announces Collaboration with FundamentalVR, to Improve Training Through Virtual Reality Simulation
August 25, 2022 06:30 ET | Teleflex Incorporated
FundamentalVR Offers Teleflex a Scalable Training Platform to Accelerate the Effective Use of the UroLift® 2 System for Treatment of Enlarged Prostate WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) --...
TeleflexLogo.jpg
Teleflex Announces Pocono Raceway NASCAR Event to Raise Visibility of Enlarged Prostate and the Importance of Regular Health Screenings
July 21, 2022 06:30 ET | Teleflex Incorporated
WAYNE, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the company is hosting a booth at the Pocono...
TeleflexLogo.jpg
New Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged Prostate
July 01, 2022 06:30 ET | Teleflex Incorporated
WAYNE, Pa., July 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the results of several research studies that...
TeleflexLogo.jpg
Teleflex Celebrates June Men’s Health Month with Launch of UroLift® Patient Ambassador Program
June 01, 2022 06:30 ET | Teleflex Incorporated
WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it is celebrating Men’s Health Month with the...
TeleflexLogo.jpg
Teleflex Announces Regulatory Clearance for its UroLift® System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)
May 19, 2022 06:30 ET | Teleflex Incorporated
WAYNE, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has received National Medical Products...
TeleflexLogo.jpg
Teleflex Announces Full U.S. Commercial Launch of the UroLift® 2 System and UroLift ATC ® Advanced Tissue Control System
May 13, 2022 06:30 ET | Teleflex Incorporated
WAYNE, Pa., May 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the full U.S. commercial launch of its UroLift® 2...
TeleflexLogo.jpg
Teleflex Announces the Launch of the UroLift® System in Japan for the Treatment of Benign Prostatic Hyperplasia (BPH)
April 11, 2022 06:30 ET | Teleflex Incorporated
WAYNE, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced the launch of the UroLift System in Japan for...
TeleflexLogo.jpg
Teleflex Receives Reimbursement Approval for the UroLift® System in Japan
December 13, 2021 06:30 ET | Teleflex Incorporated
WAYNE, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that the company has received reimbursement approval from the Central Social Insurance Medical Council...
TeleflexLogo.jpg
The UroLift® System Receives Bronze Award for Best New Branded Television Campaign and Honorable Mention in the Best Branded Website Category from DTC Perspectives
October 29, 2021 06:30 ET | Teleflex Incorporated
WAYNE, Pa., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that the UroLift® System was honored by DTC Perspectives with a Bronze Award in the “Best New Branded...